The tournament, which begins on November 9 in Morocco, promises financial support for every participating club, as each team is guaranteed at least $150,000, CAF confirmed in a statement on Thursday.
ENHERTU is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca.